BACKGROUND: In metastatic colorectal cancer (mCRC), regorafenib (RGF), a multi-kinase inhibitor with angiogenic inhibition has modest effects on survival. We reported that autophagy modulation using hydroxychloroquine (HCQ), enhances the anticancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in mCRC, is well tolerated, and has comparable activity to RGF. Thus, we conducted a prospective study of VOR/HCQ versus RGF in mCRC. METHODS: This is a randomised, controlled trial of VOR 400 mg and HCQ 600 mg orally daily versus RGF 160 mg orally daily (3 weeks on/1 week off), every 4 weeks, in patients with mCRC. PRIMARY ENDPOINT: median progression-free survival (mPFS). Secondary endpoints: median overall survival (mOS); adverse events; pharmacodynamic analyses. RESULTS: From 2/2015-10/2017, 42 patients were randomised to VOR/HCQ and RGF. Median age was 58.4 years. mPFS on VOR/HCQ was 1.9 months versus 4.35 months with RGF (P = 0.032). There was no difference in mOS (P = 0.9). Treatment was tolerated in both arms. In both arms, there was improved anti-tumour immunity. CONCLUSIONS: VOR/HCQ had an inferior PFS when compared to RGF, although there was an increase in anti-tumour immunity in mCRC. VOR/HCQ has a favourable safety profile, and immune or tumour biomarkers may be used to identify clinical benefit of autophagy modulation in mCRC. CLINICAL TRIAL REGISTRATION: NCT02316340.
BACKGROUND: In metastatic colorectal cancer (mCRC), regorafenib (RGF), a multi-kinase inhibitor with angiogenic inhibition has modest effects on survival. We reported that autophagy modulation using hydroxychloroquine (HCQ), enhances the anticancer activity of the histone deacetylase inhibitor, vorinostat (VOR), in mCRC, is well tolerated, and has comparable activity to RGF. Thus, we conducted a prospective study of VOR/HCQ versus RGF in mCRC. METHODS: This is a randomised, controlled trial of VOR 400 mg and HCQ 600 mg orally daily versus RGF 160 mg orally daily (3 weeks on/1 week off), every 4 weeks, in patients with mCRC. PRIMARY ENDPOINT: median progression-free survival (mPFS). Secondary endpoints: median overall survival (mOS); adverse events; pharmacodynamic analyses. RESULTS: From 2/2015-10/2017, 42 patients were randomised to VOR/HCQ and RGF. Median age was 58.4 years. mPFS on VOR/HCQ was 1.9 months versus 4.35 months with RGF (P = 0.032). There was no difference in mOS (P = 0.9). Treatment was tolerated in both arms. In both arms, there was improved anti-tumour immunity. CONCLUSIONS: VOR/HCQ had an inferior PFS when compared to RGF, although there was an increase in anti-tumour immunity in mCRC. VOR/HCQ has a favourable safety profile, and immune or tumour biomarkers may be used to identify clinical benefit of autophagy modulation in mCRC. CLINICAL TRIAL REGISTRATION: NCT02316340.
Authors: Julie L Lucas; Parham Mirshahpanah; Eric Haas-Stapleton; Khusru Asadullah; Thomas M Zollner; Robert P Numerof Journal: Cell Immunol Date: 2009-04-08 Impact factor: 4.868
Authors: Rachel P Riechelmann; Luiz S Leite; Giovanni M Bariani; Joao Glasberg; Thomas G Rivelli; Leonardo Gomes da Fonseca; Daniela R Nebuloni; Maria I Braghiroli; Marcelo A Queiroz; Alice M Isejima; Christian Kappeler; Luciana Kikuchi; Paulo M Hoff Journal: Oncologist Date: 2019-06-07
Authors: Janet Roberts; Michael Smylie; John Walker; Naveen S Basappa; Quincy Chu; Michael Kolinsky; Christopher Lyddell; Carrie Ye Journal: Clin Rheumatol Date: 2019-01-30 Impact factor: 2.980
Authors: Flavia Fondevila; Carolina Méndez-Blanco; Paula Fernández-Palanca; Javier González-Gallego; José L Mauriz Journal: Exp Mol Med Date: 2019-09-24 Impact factor: 8.718
Authors: Jennifer S Carew; Ernest C Medina; Juan A Esquivel; Devalingam Mahalingam; Ronan Swords; Kevin Kelly; Hui Zhang; Peng Huang; Alain C Mita; Monica M Mita; Francis J Giles; Steffan T Nawrocki Journal: J Cell Mol Med Date: 2010-10 Impact factor: 5.310
Authors: Thomas B Karasic; Timothy J Brown; Charles Schneider; Ursina R Teitelbaum; Kim A Reiss; Tara C Mitchell; Ryan C Massa; Mark H O'Hara; Lisa DiCicco; Luis Garcia-Marcano; Ravi K Amaravadi; Peter J O'Dwyer Journal: Oncologist Date: 2022-09-02 Impact factor: 5.837